The currently approved pharmacological agents for the prevention and/or treatment of osteoporosis are bisphosphonates, denosumab, parathyroid hormone, an analog of parathyroid hormone-related peptide, calcitonin, estrogens, estrogen agonist/antagonist, tissue-selective estrogen complex, and the monoclonal antibody to sclerostin (romosozumab). The gene discussed is SOST; the disease is osteoporosis.